NCT02586311

CKD-330 Phase 3 Trial in Amlodipine Non-responder

A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a CKD-330 Versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 160 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Trial to Evaluate the Efficacy and Safety of a CKD-330 versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy

Detailed description

A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a CKD-330 versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	CKD-330 16/5mg	Once a day, 8 weeks
DRUG	Amlodipine 5mg Placebo	Once a day, 8 weeks
DRUG	CKD-330 16/5mg Placebo	Once a day, 8 weeks
DRUG	Amlodipine 5mg	Once a day, 8 weeks

Timeline

• Start date: 2016-01-01
• Primary completion: 2016-08-01
• Completion: 2016-09-01
• First posted: 2015-10-26
• Last updated: 2016-10-06

Locations

1 site across 1 country: South Korea